2022
Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease
Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. Journal Of Clinical Oncology 2022, 40: 1174-1185. PMID: 35007144, PMCID: PMC8987226, DOI: 10.1200/jco.21.01755.Peer-Reviewed Original ResearchConceptsChronic GVHDAcute GVHDHost diseaseNonrelapse mortalityT cellsPeripheral blood stem cell graftsBlood stem cell graftsGrade II acute GVHDGrade III acute GVHDNaive T-cell depletionAllogeneic hematopoietic cell transplantationPhase II clinical trialChronic Graft-VersusUnrelated donor graftsT-cell depletionHematopoietic cell transplantationTotal body irradiationMemory T cellsRelapse-free survivalStem cell graftsNaive T cellsApparent excess riskCell transplantation approachesGastrointestinal GVHDGraft-Versus
2003
Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma
Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplantation 2003, 32: 763-769. PMID: 14520419, DOI: 10.1038/sj.bmt.1704233.Peer-Reviewed Original ResearchConceptsPeripheral blood stem cellsNon-Hodgkin lymphomaNonrelapse mortalityAutologous transplantAllogeneic peripheral blood stem cell transplantationPoor-prognosis non-Hodgkin's lymphomaPeripheral blood stem cell transplantationBlood stem cell transplantationHost disease (GVHD) prophylaxisMini-dose methotrexateLow-grade histologyReduced-intensity conditioningStem cell transplantationBlood stem cellsHigh-grade lymphomaAbnormal organ functionAblative regimensLymphoma effectPrevious transplantAdditional therapyIntravenous busulfanPost transplantPotent graftAllogeneic transplantsOverall survival
2000
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease
Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Annals Of Oncology 2000, 11: 665-672. PMID: 10942053, DOI: 10.1023/a:1008396525292.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsCarmustineCombined Modality TherapyCytarabineDisease-Free SurvivalEtoposideFemaleHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansL-Lactate DehydrogenaseMaleMelphalanMiddle AgedPrognosisRecurrenceTransplantation, AutologousConceptsProgression-free survivalHigh-dose BEAM chemotherapyPeripheral blood progenitor cellsAutologous PBPC transplantationTime of transplantationPrimary refractoryHodgkin's diseaseHigh-dose BEAMBEAM chemotherapyPBPC transplantationOverall survivalAutologous peripheral blood progenitor cell transplantationAutologous peripheral blood progenitor cellsPeripheral blood progenitor cell transplantationBlood progenitor cell transplantationSatisfactory progression-free survivalSevere non-hematologic toxicityWorse progression-free survivalPoor progression-free survivalAutologous PBPC infusionNon-hematologic toxicitiesTransplant-related complicationsConsecutive adult patientsElevated lactate dehydrogenaseRelapse/progression